Orphan Drug Designation
We Are Advancing Immunology Solutions for a Better Future.
Orphan Drug Designation is a status given to certain drugs targeting rare disease or conditions that affect fewer than 200,000 people for the United States and for Europe, fewer than 5 in 10,000 people.
| Product Candidate | Country | Indication |
| Ampligen® | USA | CFS/ME |
| Ampligen® | USA | HIV |
| Ampligen® | USA | Metastatic Melanoma |
| Ampligen® | USA | Renal Cell Carcinoma |
| Ampligen® | USA | Pancreatic Adenocarcinoma |
| Ampligen® | European Union | Pancreatic Adenocarcinoma |
| Ampligen® | USA | Ebola Virus Disease |
| Ampligen® | European Union | Ebola Virus Disease |
| Alferon N Injection® | European Union | MERS |
Orphan Drug Designation Provides a Number of Incentives Including:
United States